At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 657 enrolled
Drug / intervention
Mupirocin Calcium +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo's Mupirocin Cream to A Reference Manufacturer's Mupirocin Cream and to Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions
In Brief
A Phase 3 clinical trial evaluating Mupirocin Calcium and Vehicle for Secondarily Infected Traumatic Skin Lesions. Completed, enrolled 657 participants across 1 site.
Detailed Summary
To compare the safety and efficacy of Perrigo's product to an FDA approved product, and to Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedNov 2019
Primary CompletionJun 2021
TodayJul 2026
First PostedNov 7, 2019
Enrollment StartOct 15, 2019
Primary CompletionJun 1, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.7 years ago
Interventions
Mupirocin Calciumdrug
mupirocin cream
Mupirocin Calciumdrug
Reference mupirocin cream
Vehicledrug
vehicle control cream